Introduction
Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes currently available for human gene therapy in that they are based upon a class of viruses that commonly inhabits a human host without causing any detectable pathology. This fact, combined with the propensity of AAV to establish long-term persistence in human cells, could lead one to hypothesize that this class of vectors would be ideal for a variety of gene therapy approaches. However, a number of significant limitations to the utility of this system have recently been identified, including the paucity of cell surface receptors on some cells for the most common AAV serotype, AAV2, the loss of site-specific integration by recombinant AAV vectors, and the presence of host immune responses to AAV capsid components and transgene products. Driven by these limitations, new generations of rAAV vectors have recently emerged, based on a number of alternative AAV serotypes or on designer mutants of the AAV capsid, which have been retargeted for entry into previously nonpermissive cells. Finally, a deeper understanding of the mechanisms of AAV integration and persistence promise to make it possible to recapture the best features of the native virus and allow this system to move forward into broader clinical application.
Many new AAV serotypes have been discovered
The AAVs are single-stranded DNA-containing nonenveloped icosahedral viruses that were first discovered as contaminants of adenovirus cultures, and subsequently were found to be common inhabitants of the human respiratory and gastrointestinal tract. AAVs generally require a helper virus, such as adenovirus, herpesviruses, or vaccinia, in order to replicate themselves in the productive phase of their life cycle. In the absence of helper virus, AAVs have the capacity to establish long-term latency within mammalian cells. They possess several features that are unique among mammalian viruses, including the nonpathogenic nature of AAV infections and the capacity of AAV-2 to integrate its proviral DNA into a specific region of human chromosome 19, the AAVS1site. When cells latently infected with AAV are subsequently infected with a helper virus, the AAV can be rescued and reenter the replicative phase of the life cycle. AAV is capable of carrying out all functions necessary for completing its life cycle with a remarkably small (4.7 kb) and simple genome structure. There are two genes, rep and cap, flanked by two inverted terminal repeats (ITRs) that contain all the cis-acting sequences necessary for packaging, replication, and integration of the vector genome. Recent studies also indicate that the ITRs possess some transcriptional promoter activity, albeit relatively weak. 1 The rep gene encodes the four nonstructural Rep proteins (Rep78, Rep68, Rep52, and Rep40) that are necessary for resolution of the termini during productive replication. This is accomplished by means of a site-specific, strandspecific nicking activity present in the longer Rep proteins, which are transcribed from the p5 promoter, and differ only at the C-terminus, where spliced and unspliced versions are both translated. These longer Rep proteins are also bifunctional transcription regulators, which generally activate AAV gene expression during productive infection and repress it during latency. The shorter Rep proteins are transcribed from the p19 promoter, which is embedded within the long Rep coding sequence. The shorter Reps are necessary for packaging single-stranded AAV genomes into capsids. They also modify the transcriptional regulatory activities of the longer Reps. All AAVs sharing these properties are members of the genus Dependovirus, of the virus family Parvovidae, subfamily Parvovirinae. There are currently 11 genus members recognized by the International Committee for Taxonomy of viruses, including AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, avian AAV, bovine AAV, canine AAV, equine AAV, and ovine AAV (available at http://www.ncbi.nlm.nih.gov/ICTV/).
Recently, a number of new types of AAV have been identified by screening human and nonhuman primate tissues for the presence of rescuable AAV genomes. Over 40 genomic variants having been reported. 2 It appears that there are several major clades of related variants. Within these clades, many other individual variants appear to have been generated by recombination within the capsid coding sequence between different parental serotypes. The utility of each of these capsid variants as potential serotypes or pseudotypes for gene transfer is currently being investigated.
Structural biology of AAV opens the door to new vector designs
The capsid gene encodes the three structural proteins, VP1, VP2, and VP3. These three proteins are colinear and identical over their carboxy-terminal portion. VP2 and VP3 represent amino-terminal truncations of VP1. The typical AAV capsid consists of 60 molecules of capsid protein, with a ratio of 3:3:54 of VP1:VP2:VP3 in a nonenveloped icosahedral structure. The crystal structure of AAV2 has recently been published. 3 The structural determinants of AAV2 receptor binding to the heparan sulfate proteoglycan attachment receptor have also been delineated by various mutagenesis studies. 4, 5 The differences in binding affinity to different receptors among the various serotypes are likely to be accounted for by differences within these structural determinants, since the key heparin-binding residues are different on nonheparin-binding serotypes. 6, 7 Receptor-targeted capsid mutants and alternative serotypes broaden the host range for rAAV-mediated gene transfer
The relative inefficiency of rAAV2-based gene delivery has led to studies of potential barriers to efficient gene transfer in tissues like lung. 6 The first of these barriers to be clearly identified was the relative paucity of the common AAV2 attachment receptor, heparan sulfate proteoglycan, on the apical surface of polarized ciliated respiratory epithelial cells. Comparison with vectors packaged in AAV5-based capsids, which utilize N-linked sialic acid as an attachment receptor indicated that this receptor abundance issue could be a major limiting factor to the efficiency of airway epithelial cell transduction. 6, 7 The potential utility of the newly available pseudotyped rAAV vectors for improved transduction of other organs, such as liver and muscle have also been studied. 8, 9 These tend to indicate a significant advantage of rAAV1 vectors for muscle transduction and of rAAV6 in the liver.
The receptor tropisms of most of the new AAV serotypes have not yet been defined. As mentioned above, it is known that AAV5 binds to N-linked sialic acid, while AAV4 binds to O-linked sialic acid. 7 One issue that has not been well-defined, except for AAV2 is that of coreceptors required for efficient entry once viral capsids have bound to the cell surface. In the case of AAV2, it appears that either alpha V -beta 5 integrins or the fibroblast growth factor receptor-1 can function as a coreceptor. Coreceptors for the other serotypes have not yet been identified. Importantly, it has been demonstrated in vitro that viral tropism can be changed by inserting ligands specific for relatively resistant cells into the capsid protein. The targeting of receptors such as the serpin enzyme complex receptor, 5 the LDL-receptor, 10 and several others 11 have been successful. Even in tissues, like skeletal muscle, where rAAV2-based vector transduction appears to be relatively robust, substantial increases in vector transduction efficiency can be observed by the use of alternative serotype capsids. For instance, an improvement of transduction efficiency with rAAV2-based vectors of several-hundred fold was observed in factor IX and AAT vectors crosspackaged into rAAV1 capsids. 12 Similar enhancement of transduction efficiency has also been seen in the central nervous system with other serotypes, although in that case, the pattern of cell types transduced also differs based on which serotype capsid was used. of the serotype-specific differences in gene transfer efficiency. In particular, rAAV2-based vectors when exposed to the apical surface of polarized airway epithelial cells appear to be capable of entering the cells with reasonably high efficiency. 14 However, the efficiency of nuclear entry is quite poor, 15, 16 and can be enhanced by inhibition of proteosome function. 14 Paradoxically, ubiquitination appears to be required for entry into the nucleus by this pathway. 17 This implies a complex series of trafficking signals necessary for vector to be transported to the nucleus, and these events may differ based on the cell type or polarity of vector entry into the cell. 15, 18 In any case, the newly widened availability of alternate AAV capsid serotypes and receptor-specific mutants promises to provide means for bypassing the various obstacles to vector entry.
Once within the nucleus, the vector DNA must be converted from single-stranded DNA to double-stranded DNA in order to be transcriptionally active, a potentially inefficient process. The mechanism by which this usually occurs appears to be leading strand synthesis. This process appears to be regulated by the phosphorylation state of a single-stranded d-sequence binding protein, which has been identified to be a member of the FK506 protein-binding protein (FKBP) family. 19 One way around this particular problem has recently been described. This method involves the design of vectors that represent selfcomplementary doublets of the sequence of interest, capable of folding back upon themselves upon uncoating of the virus to produce a vector genome that very rapidly becomes transcriptionally active. 20 New data on the mechanisms of rAAV persistence help define potential risks and benefits of rAAV-mediated transduction Once double-stranded DNA is produced, a mechanism must be operative for stable persistence of that vector DNA. In the case of quiescent cells, Rep-deleted AAV vectors have demonstrated a propensity to form stable concatemers, apparently by nonhomologous end-joining of vector monomer genomes. 21 Incidentally, this mechanism may also be taken advantage of to overcome the inherent packaging limit of AAV, by packaging two half molecules with splice donor and splice acceptor sites into two different populations of vector particles. Once these particles coinfect a target cell, concatemer formation will allow for the production of a full-length active vector. [22] [23] [24] In the case of proliferating cells, the lack of efficient integration in the absence of Rep may be problematic. Several groups have demonstrated that it may be feasible to add Rep back in trans in order to effect site-specific integration. The efficiency of this process appears to be lower than that seen for wild-type virus, however, suggesting that cis-acting sequences outside of the ITRs proper are required for efficient site-specific integration.
Progress in rAAV production technology makes new applications feasible rAAV vectors were originally constructed by deleting portions of the AAV rep and cap genes and replacing these with genes of interest, demonstrating that only the ITRs are required in cis for replication and packaging of rAAV genomes, so long as rep, cap, and helper virus functions are provided in trans (Figure 1) . The packaging limit of rAAV is approximately 5 kb. Refinements of the rAAV packaging and purification process have been numerous over the years.
Recent protocols have emphasized a potential increase in upstream production yields by using Ad gene plasmids in lieu of active Ad infection of packaging cells, and by moderating the amount of long Rep (Rep78 and Rep68) proteins expressed relative to short Reps (52/40) and capsid. Other improved production methods have included the use of stable cell lines with inducible Rep expression and rescuable vector genomes or the use of herpes simplex virus amplicons or recombinants. Recent purification strategies have sought to avoid CsCl ultracentrifugation, which seems to decrease the infectivity of vector material, and favoring column chromatography methods.
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The availability of high-titer, highly purified rAAV2 vector preparations, free of replication-competent (rc)-AAV has allowed for testing of rAAV2 gene delivery in numerous in vivo settings, including many rodent and nonhuman primate models. rAAV gene delivery was demonstrated in the lungs of rabbits, mice, and rhesus macaques in the context of the development of rAAV2-CFTR vectors for the treatment of cystic fibrosis (CF). 28 These studies indicated that rAAV2 gene delivery to the lung was feasible, safe and persistent. Surprisingly, persistence was associated with stable episomal forms of the vector genome, rather than with integration. Indeed, the crucial role of the rAAV Rep protein (which is deleted from most rAAV2 vectors) in driving integration has since been confirmed.
Subsequent studies showed that rAAV2 gene delivery was much more efficient in terminally differentiated neurons, retinal cells, 29 and myofibers. The delivery of rAAV2 vectors to the liver has also been demonstrated to be very efficient. [30] [31] [32] [33] [34] [35] rAAV2-based gene delivery to muscle and liver has been shown to be quite effective for delivery of secreted proteins, such as factor IX and alpha-1 antitrypsin 34, 35 (Figure 2 ). 
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Clinical trials utilizing rAAV are expanded
The use of rAAV2 in early-phase clinical trials has been reported for two diseases, cystic fibrosis (CF) and hemophilia B. In the case of CF, three phase I trials and two phase II trials have been performed. [36] [37] [38] The phase I trials have included delivery to the nose, maxillary sinus, and lung, with the latter organ approached both by direct bronchoscopic instillation and by aerosol inhalation. Phase II studies of maxillary sinus and aerosol administration have also been completed recently. Taken together, these studies generally indicate a lack of any vector-mediated toxicity, and a surprisingly efficient rate of DNA transfer. The phase II aerosol trial also showed evidence of a decrease in pulmonary inflammation and an increase in pulmonary function, both of which were statistically significant in this randomized, placebocontrolled, double-blinded study. The effects lasted only for 30 days, however, and repeated administration did not appear to be capable of sustaining the positive effects. This appears to relate to the development of neutralizing antibodies to AAV2 capsid components.
The studies in patients with hemophilia B have yielded somewhat similar results. 39, 40 Gene transfer has been documented, and transient evidence of biological activity has been demonstrated. However, the efficiency and persistence of gene delivery does not appear to be sufficient for long-term therapeutic efficacy so far. In the case of hemophilia, it appears that immune responses to the transgene product, as well as the vector capsid may be the cause of some of the limitation, particularly when vector is administered by the intramuscular route. This could relate to the potential for factor IX binding the extracellular matrix in muscle, as has been demonstrated in factor IX-deficient mice. Because of this concern, the focus of trials has recently moved from intramuscular to intrahepatic administration. Although very few subjects have been enrolled to date, reports of transient presence of vector DNA sequences in the semen of male subjects has been a cause for increased scrutiny in these particular trials.
As with the animal studies, the clinical trials have brought into focus a number of potential limitations to the rAAV vector platform. The limitations include a number of potential barriers to efficient entry, the lack of stable persistence of vector DNA within cell targets that are proliferating, which limits persistence, and the immune response to the vector capsid, which limits readministration. Finally, there remains the inherent limitation due to the constrained packaging capacity of the AAV capsid (5 kb total).
Barriers to rAAV-mediated gene transfer in the clinical setting are identified
The potential limitations to rAAV-based gene delivery can be considered in the context of the steps that must be accomplished before efficient, persistent gene transfer and expression can occur. The first potential obstacle is efficient delivery and distribution to the appropriate cell surface. For some cells, such as the airway epithelial cells lining the airways of CF patients with pre-existing lung disease, a complex mixture of cellular and bacterial products is present within the airway lumen potentially providing an important extracellular barrier to gene transfer, 41 although the significance of this effect has recently been called into question. 42 Another important potential extracellular blockade to cellular attachment could be posed by the presence of extracellular neutralizing anti-capsid antibodies. Interestingly, clinical studies have not shown that pre-existing anti-AAV antibodies form a significant barrier to vector entry. However, repeated dosing and its associated rise in anti-AAV antibodies do appear to prevent efficient readministration, particularly in the respiratory tract. Although secreted IgA antibody has not been demonstrated, it does appear that compartmentalized immune responses may play a role. Another potential impediment to efficient delivery of vector to the target cell may occur when there is only a very brief time of contact between vector and host cell. This most prominently may occur within the lumen of vascular structures or airways, where vector may be swept along in the current of intralumenal fluid flow. The feasibility of surmounting this problem by reversibly binding vector to latex microspheres has recently been demonstrated. 43 
Barriers to repeated dosing of rAAV
The potential for repeated dosing of rAAV vectors has been studied in a number of preclinical models and utilizing a number of different modes of administration. In the case of airway surface administration, Beck et al reported that repeated administration of rAAV2 to rabbits by bronchoscopy led to the development of increasing titers of anti-AAV2 neutralizing antibodies. In that system, a third successive dose of rAAV vector yielded a lower (but not absent) efficiency of gene transfer, while an AAV3 pseudotyped vector was relatively unaffected. In a similar paradigm, Halbert et al reported a more dramatic decrement in efficiency of subsequent doses with rAAV2 vectors, an effect that Recombinant rAAV vectors TR Flotte could be abrogated by transient immunosuppression. However, they did not see as great an effect with rAAV6-based vectors. 44 Clinical trial data, like the animal data, indicate a consistent increase in serum neutralizing antibodies after dosing with rAAV2-CFTR, but inconsistent effect on blocking of gene transfer via the airway lumen. In all clinical trials, the level of pre-existing serum neutralizing antibodies was not predictive of gene transfer. [36] [37] [38] Taken in aggregate, these data suggest that the presence of serum neutralizing IgG antibodies may indicate that a humoral immune response to capsid components has occurred, but is not fully predictive of mucosal (most likely IgA-mediated immunity). If, as is generally the case, the IgA-mediated immunity is less persistent than the IgG-mediated immunity, a longer interval between doses may be indicated. Less data are available for intramuscular injection, but there again humoral responses to capsid have been observed. Unlike lung delivery, however, intramuscular gene transfer with rAAV has generally resulted in life-long effects, potentially obviating the repeated dosing issue.
Use of small molecules to overcome intracellular barriers to rAAV transduction AAV vectors as a class appear to have the most important properties necessary for successful gene therapy, namely they are relatively nontoxic and are potentially capable of long-term persistence in human cells. A variety of obstacles to efficient gene delivery and persistence have been identified recently, allowing for more focused efforts to improve the technology. Fundamentally, none of these limitations appears to be intractable and early clinical trials show hopeful signs that the remarkable safety profile of this vector will hold true in its derivation as a human therapeutic agent. Most challenging will be the achievement of the final goal of life-long persistence, which based on the virus life cycle, does appear to be ultimately within reach. If this can be reproducibly achieved, the potential for curative therapy could follow close behind.
One of the most immediate modifications that could come into clinical trial applications would be the use of small molecule proteasome inhibitors to enhance the delivery of rAAV vectors to the nucleus of transduced cells. 17 While this effect has been demonstrated in both liver and lung, the application of proteasome inhibitors in the context of rAAV2-CFTR gene transfer to the lungs seems to be the closest to practical application.
Clinical applications based on achieving sustained secretion of extracellular transgene products
The most likely applications to succeed in the clinical setting may be those in which an existing protein replacement therapy could be supplanted by gene transfer to a nondividing tissue, like skeletal muscle, resulting in sustained secretion of the therapeutic protein into the circulation. Factor IX may be able to prove that concept, but other candidates, such as alpha-1 antitrypsin (AAT) are moving rapidly towards clinical trial. One key to this process is likely to be the avoidance of immune responses to the transgene. If that is the case, proteins like AAT that have not been prone to immune responses in the context of existing protein replacement therapies, are good candidates.
Gene modification approaches to regenerative medicine
In the future, the potential use of stem cell-derived cell platforms with gene transfer might allow for a maximally beneficial approach to regenerative medicine. 45 In the stem cell context, one must consider that autologous stem cells may be prone to recurrence of the underlying disease that led to end-organ damage originally. Meanwhile, the use of allogeneic stem cells will entail immune suppression just as it does in solid organ transplantation. Only through gene-modification of autologous stem cells can the full potential of regenerative medicine be realized.
